Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Open accessAbstract
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and variable clinical course. Although matrix metalloproteinase‐7 (MMP‐7) is emerging as an important IPF biomarker, reproducibility across studies is unclear. We aimed to determine whether a previously reported prognostic threshold for MMP‐7 was predictive of mortality in an independent cohort of IPF patients. Methods: MMP‐7 concentrations obtained from heparinized plasma samples were determined by ELISA in 97 patients with IPF and 41 healthy controls. The association of the previously published heparin plasma MMP‐7 threshold of 12.1 ng/mL with all‐cause mortality or transplant‐free survival (TFS) was determined, either as an independent biomarker or as part of the modified personal clinical and molecular mortality index (m‐PCMI). Results: MMP‐7 plasma concentrations were significantly higher in IPF patients compared to healthy controls (14.40 ± 6.55 ng/mL vs 6.03 ± 2.51 ng/mL, P < 0.001). The plasma MMP‐7 threshold of 12.1 ng/mL was significantly associated with both all‐cause mortality and TFS (unadjusted Cox proportional hazard ratio (HR) = 25.85 and 15.49, 95% CI: 10.91–61.23 and 5.41–44.34, respectively, P < 0.001). MMP‐7 concentrations, split by 12.1 ng/mL, were significantly (P < 0.05) predictive of mortality and TFS after adjusting for age, gender, smoking and baseline pulmonary function parameters, in a multivariate Cox proportional hazards model. MMP‐7 concentrations were negatively correlated with diffusing lung capacity of carbon monoxide (DL CO) (r = −0.21, P = 0.02), and positively with a mortality risk scoring system (GAP) that combines age, gender, forced vital capacity (FVC) and DL CO (r = 0.32, P = 0.001). Conclusion: This study confirms that MMP‐7 concentrations could be used to accurately predict outcomes across cohorts and centres, when similar collection protocols are applied.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MMP-7 and OPN are predictive and prognostic biomarkers for IPF, and sICAM-1 and CTGF protein levels are elevated in the blood serum and plasma of IPF patients.
“MMP-7 and OPN are described as predictive and prognostic biomarkers for IPF, with sICAM-1 and CTGF protein levels being elevated in the blood serum and plasma of IPF patients (Guiot et al., 2017;Kono et al., 2011;Tzouvelekis et al., 2017;White et al., 2016).”
From PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells (2024) · cites this paper as Tzouvelekis et al., 2017
The Results and Discussion (page not specified) support plasma MMP-7 as a marker of IPF and a predictor of mortality. The Discussion mentions osteopontin only as a substrate of MMP-7, not as a predictive or prognostic biomarker; the paper provides no finding that sICAM-1 or CTGF is elevated in patients’ serum or plasma. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMMP7 is consistently elevated in patients with IPF compared with healthy controls, and MMP7 levels above 12.1 ng/mL are predictive of all-cause mortality and correlate with poorer transplant-free survival.
“Among the promising biomarkers representing epithelial cell dysfunction, MMP7 is consistently elevated in patients with IPF compared with healthy controls. MMP7 levels above a threshold level (12.1 ng/mL) are predictive of all-cause mortality and correlate with poorer transplant free survival.”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Tzouvelekis et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916 · see citing works
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · see citing works
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308 · see citing works
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853 · see citing works
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809 · see citing works
Self-citationWells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686 · see citing works
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622 · see citing works
Zuo, F., Kaminski, N., Eugui, E. M., Allard, J. D., Zohar Yakhini, B., Ben‐Dor, A., Lollini, L. O., Morris, D. G., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620 · see citing works
Self-citationNoth, I., Zhang, Y., Ma, S., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P. G., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 605 · see citing works
Self-citationMMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 582 · see citing works
Self-citationStat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K., Firpo, M., Mulvihill, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 531 · see citing works
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · see citing works
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K. F., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 492 · see citing works
Self-citationPeljto, A. L., Zhang, Y., Fingerlin, T. E., Ma, S., Garcia, J. G. N., Richards, T. J., Silveira, L. J., Lindell, K. O., Steele, M. P., Loyd, J. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.5827 · Cited by 453 · see citing works
Self-citationNew cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
Fernandez, I. E., & Eickelberg, O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61144-1 · Cited by 434 · see citing works
Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
du Bois, R. M., Weycker, D. A., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A. I., LANCASTER, L. H., Noble, P. W., Raghu, G., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1790oc · Cited by 423 · see citing works
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S. L., Creamer, A. W., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 390 · see citing works
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381 · see citing works
Self-citationHerazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325 · see citing works
Self-citationSerum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis
Greene, K. E., King, T. E., Kuroki, Y., Bucher‐Bartelson, B., Hunninghake, G. W., Newman, L. S., Nagae, H., & Mason, R. J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00081102 · Cited by 316 · see citing works
Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis
Pardo, A., Cabrera, S., Maldonado, M., & Selman, M. (2016) · Respiratory Research · doi:10.1186/s12931-016-0343-6 · Cited by 307 · see citing works
Prognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis
Yokoyama, A., KONDO, K., Nakajima, M., Matsushima, T., Takahashi, T., Nishimura, M., Bando, M., Sugiyama, Y., Totani, Y., Ishizaki, T., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00834.x · Cited by 304 · see citing works
Matrix metalloproteinase proteomics: substrates, targets, and therapy
Morrison, C., Butler, G. S., Rodrı́guez, D., & Overall, C. M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.06.006 · Cited by 266 · see citing works
Detection of Rheumatoid Arthritis–Interstitial Lung Disease Is Enhanced by Serum Biomarkers
Doyle, T. J., Patel, A. S., Hatabu, H., Nishino, M., Wu, G., Osorio, J. C., Golzarri, M. F., Traslosheros, A., Chu, S. G., Frits, M. L., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-1950oc · Cited by 216 · see citing works
Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., McCormack, F. X., Ix, J. H., Kervitsky, A., Schwarz, M. I., & King, T. E. (2009) · CHEST Journal · doi:10.1378/chest.08-2209 · Cited by 208 · see citing works
White, E. S., Xia, M., Murray, S., Dyal, R., Flaherty, C. M., Flaherty, K. R., Moore, B. B., Cheng, L., Doyle, T. J., Villalba, J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0862oc · Cited by 180 · see citing works
Kropski, J. A., Pritchett, J. M., Zoz, D. F., Crossno, P. F., Markin, C. R., Garnett, E. T., Degryse, A. L., Mitchell, D. B., Polosukhin, V. V., Rickman, O. B., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1162oc · Cited by 178 · see citing works
Molecular biomarkers in idiopathic pulmonary fibrosis
Ley, B., Brown, K. K., & Collard, H. R. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2014 · Cited by 170 · see citing works
Palliative Care and Location of Death in Decedents With Idiopathic Pulmonary Fibrosis
Lindell, K. O., Liang, Z., Hoffman, L. A., Rosenzweig, M. Q., Saul, M. I., Pilewski, J. M., Gibson, K. F., & Kaminski, N. (2014) · CHEST Journal · doi:10.1378/chest.14-1127 · Cited by 166 · see citing works
Self-citationBiomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Chen, J., Doyle, T. J., Liu, Y., Aggarwal, R., Wang, X., Shi, Y., Ge, S., Huang, H., Lin, Q., Liu, W., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38904 · Cited by 146 · see citing works
Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., et al. (2016) · Disease Markers · doi:10.1155/2016/4759040 · Cited by 140 · see citing works
Blood Biomarkers MMP-7 and SP-A
Song, J. W., Do, K., Jang, S. J., Colby, T. V., Han, S., & Kim, D. S. (2013) · CHEST Journal · doi:10.1378/chest.11-2735 · Cited by 137 · see citing works
Szarvas, T., Becker, M., Dorp, F. V., Gethmann, C., Tötsch, M., Bánkfalvi, Á., Schmid, K. W., Romics, I., Rubben, H., & Ergün, S. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01506.x · Cited by 110 · see citing works
Fujishima, S., Shiomi, T., Yamashita, S., Yogo, Y., Nakano, Y., Inoue, T., Nakamura, M., Tasaka, S., Hasegawa, N., Aikawa, N., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0144-oa.1 · Cited by 88 · see citing works
Morais, A., Beltrão, M., Sokhatska, O., Costa, D., Melo, N., Mota, P. C., Marques, A., & Delgado, L. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.003 · Cited by 78 · see citing works
Richards, T. J., Park, C., Chen, Y., Gibson, K. F., Di, Y. P., Pardo, A., Watkins, S. C., Choi, A. M. K., Selman, M., Pilewski, J. M., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00319.2011 · Cited by 48 · see citing works
Self-citationPersonalized medicine in idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Maher, T. M. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000187 · Cited by 46 · see citing works
(2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.1925erratum · Cited by 46 · see citing works
Impact of Blood Sampling on the Circulating Matrix Metalloproteinases 1, 2, 3, 7, 8, and 9
Jung, K., Klotzek, S., Stephan, C., Mannello, F., & Lein, M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099937 · Cited by 45 · see citing works
Meisser, A., Cohen, M., & Bischof, P. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.041707 · Cited by 35 · see citing works
Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
Τzouvelekis, Α., Herazo‐Maya, J. D., Sakamoto, K., & Bouros, D. E. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666150930120959 · Cited by 33 · see citing works
Self-citationMMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study
Ulivi, P., Casoni, G. L., Foschi, G., Scarpi, E., Tomassetti, S., Romagnoli, M., Ravaglia, C., Mengozzi, M., Zoli, W., & Poletti, V. E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224097 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S. L., Creamer, A. W., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 390 · see citing works
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271 · see citing works
Li, N., Kaur, P., Bunnag, N., Suresh, J., Sung, I. C. H., Tan, Q. H., Gruber, J., & Tolwinski, N. S. (2019) · Cells · doi:10.3390/cells8080826 · Cited by 219 · see citing works
“In idiopathic pulmonary fibrosis (IPF), immunohistochemical analyses reveal that MMP7 is consistently upregulated [248].”
BackgroundHerazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30349-1 · Cited by 175 · see citing works
Self-citationMonocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., & Maher, T. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0669oc · Cited by 188 · see citing works
Self-citationPrecision medicine advances in idiopathic pulmonary fibrosis
Karampitsakos, Τ., Juan-Guardela, B. M., Τzouvelekis, Α., & Herazo‐Maya, J. D. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104766 · Cited by 147 · see citing works
Self-citationInoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133 · see citing works
Shao, T., Shi, X., Yang, S., Zhang, W., Li, X., Shu, J., Alqalyoobi, S., Zeki, A. A., Leung, P. S. C., & Shuai, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684699 · Cited by 134 · see citing works
Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play
Chuliá‐Peris, L., Carreres-Rey, C., Gabasa, M., Alcaraz, J., Carretero, J., & Pereda, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136894 · Cited by 121 · see citing works
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 117 · see citing works
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132 · see citing works
on behalf of the IPF-PRO Registry investigators, Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R. A., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1103-4 · Cited by 105 · see citing works
Biomarker signatures for progressive idiopathic pulmonary fibrosis
Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01181-2021 · Cited by 86 · see citing works
Khalili‐Tanha, G., Radisky, E. S., Radisky, D. C., & Shoari, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06447-w · Cited by 90 · see citing works
Adegunsoye, A., Alqalyoobi, S., Linderholm, A., Bowman, W. S., Lee, C. T., Pugashetti, J. V., Sarma, N., Ma, S.-F., Haczku, A., Sperling, A., et al. (2020) · Chest · doi:10.1016/j.chest.2020.04.066 · Cited by 82 · see citing works
Jee, A. S., Sahhar, J., Youssef, P. P., Bleasel, J. F., Adelstein, S., Nguyen, M., & Corte, T. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.014 · Cited by 71 · see citing works
Afratis, N. A., Klepfish, M., Karamanos, N. K., & Sagi, I. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.004 · Cited by 70 · see citing works
Elhaï, M., Avouac, J., & Allanore, Y. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.01.006 · Cited by 71 · see citing works
Matson, S. M., Lee, J. S., & Eickelberg, O. (2020) · European Respiratory Journal · doi:10.1183/13993003.02533-2020 · Cited by 68 · see citing works
Karampitsakos, Τ., Torrisi, S. E., Antoniou, K. M., Manali, E. D., Korbila, I. P., Παπαϊωάννου, Ο., Sampsonas, F., Katsaras, M., Vasarmidi, E., Papakosta, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01725-9 · Cited by 69 · see citing works
Self-citationCurrent Concepts of Biliary Atresia and Matrix Metalloproteinase-7: A Review of Literature
Nomden, M., Beljaars, L., Verkade, H. J., Hulscher, J. B. F., & Olinga, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.617261 · Cited by 64 · see citing works
“In other pathologies, MMP-7 as serum or urine marker correlates very well to clinical symptoms as well as prognosis (124, 130, 148).”
BackgroundInfluentialKhan, F., Stewart, I. D., Saini, G., Robinson, K. A., & Jenkins, G. R. (2021) · European Respiratory Journal · doi:10.1183/13993003.01612-2021 · Cited by 57 · see citing works
Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis
Vukmirovic, M., & Kaminski, N. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00087 · Cited by 55 · see citing works
Self-citationPulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57 · see citing works
Tomos, I. P., Tzouvelekis, A., Aidinis, V., Manali, E. D., Bouros, E., Bouros, D. E., & Papiris, S. A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1300533 · Cited by 51 · see citing works
“levels highly correlated with disease progression [135].”
Self-citationThe current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 52 · see citing works
Post-COVID-19 Pulmonary Fibrosis
Mohammadi, A., Balan, I., Yadav, S., Matos, W. F., Kharawala, A., Gaddam, M., Sarabia, N., Koneru, S. C., Suddapalli, S. K., & Marzban, S. (2022) · Cureus · doi:10.7759/cureus.22770 · Cited by 54 · see citing works
“It may be accurately used in distinguishing IPF from other chronic pulmonary diseases [47].”
BackgroundSustained amphiregulin expression in intermediate alveolar stem cells drives progressive fibrosis
Zhao, R., Wang, Z., Wang, G., Geng, J., Wu, H., Liu, X., Bin, E., Sui, J., Dai, H., & Tang, N. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.07.004 · Cited by 51 · see citing works
Armstrong, H. F., Podolanczuk, A. J., Barr, R. G., Oelsner, E. C., Kawut, S. M., Hoffman, E. A., Tracy, R. P., Kaminski, N., McClelland, R. L., & Lederer, D. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0254oc · Cited by 47 · see citing works
“001 White 156 (51) 115 (37) 89 (29) 66 (22) Chinese 23 (8) 47 (15) 60 (20) 38 (12) Black 66 (22) 76 (25) 75 (24) 122 (40) Hispanic 60 (20) 70 (23) 84 (27) 80 (26) BMI, kg/m(2), mean6 SD 28.”
ResultSelf-citationMajewski, S., Szewczyk, K., Żal, A., Białas, A. J., Miłkowska-Dymanowska, J., & Piotrowski, W. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173864 · Cited by 45 · see citing works
Reininger, D., Fundel‐Clemens, K., Mayr, C. H., Wollin, L., Laemmle, B., Quast, K., Nickolaus, P., & Herrmann, F. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17303 · Cited by 48 · see citing works
“…such as MMP-7, OPN, sICAM-1 and CTGF. MMP-7 and OPN are described as predictive and prognostic biomarkers for IPF, with sICAM-1 and CTGF protein levels being elevated in the blood serum and plasma of IPF patients (Guiot et al., 2017; Kono et al., 2011; Tzouvelekis et al., 2017; White et al., 2016).”
The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Behr, J., Salisbury, M. L., Walsh, S. L. F., Podolanczuk, A. J., Hariri, L. P., Hunninghake, G. M., Kolb, M. R. J., Ryerson, C. J., Cottin, V., Beasley, M. B., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0048pp · Cited by 41 · see citing works
Biomarkers of cellular senescence in idiopathic pulmonary fibrosis
Aversa, Z., Atkinson, E. J., Carmona, E. M., White, T. A., Heeren, A. A., Jachim, S. K., Zhang, X., Cummings, S. R., Chiarella, S. E., LIMPER, A. H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02403-8 · Cited by 39 · see citing works
Lee, J. D., Kim, H. Y., Kang, K., Jeong, H. G., Song, M., Tae, I. H., Lee, S. H., Kim, H.-R., Lee, K., Chae, S., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02657-x · Cited by 39 · see citing works
Türkkan, G., Willems, Y. C. P., Hendriks, L. E. L., Mostard, R. L. M., Conemans, L. H., Gietema, H. A., Mitea, C., Peeters, S., & Ruysscher, D. D. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.020 · Cited by 36 · see citing works
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37 · see citing works
Jaffar, J., Wong, M., Fishbein, G. A., Alhamdoosh, M., McMillan, L., Gamell, C., Ng, M., Wilson, N. S., Symons, K., Glaspole, I., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00191-2022 · Cited by 35 · see citing works
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective
Saito, S., Lasky, J. A., Hagiwara, K., & Kondoh, Y. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.06.002 · Cited by 34 · see citing works
Lung cell transplantation for pulmonary fibrosis
Krentsis, I. M., Zheng, Y., Rosen, C., Shin, S. Y., Blagdon, C., Shoshan, E., Qi, Y., Wang, J., Yadav, S. K., Lustig, E. B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2524 · Cited by 33 · see citing works
“Although the antifibrotic drugs pirfenidone ( 6 , 7 , 15 – 18 ) and nintedanib ( 19 – 22 ) can slow disease progression to some extent, the only treatment with the proven capability to improve survival is lung transplantation ( 23 ).”
Matrisome-Associated Gene Expression Patterns Correlating with TIMP2 in Cancer
Peeney, D., Fan, Y., Nguyen, T., Meerzaman, D. M., & Stetler‐Stevenson, W. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-56632-3 · Cited by 32 · see citing works
Mårdh, C. K., Root, J. A., Uddin, M., Stenvall, K., Malmgren, A., Karabelas, K., & Thomas, M. J. (2017) · Journal of Immunology Research · doi:10.1155/2017/5273201 · Cited by 31 · see citing works
“It may be that MMPs from other sources may play a more significant role in the development of respiratory diseases such as MMP-12 from macrophages [109] or MMP-7 from hyperplastic epithelial cells in idiopathic pulmonary fibrosis [110, 111].”
Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo
Ma, Z., Zhao, C., Chen, Q., Yu, C.-H., Zhang, H., Zhang, Z., Huang, W., & Shen, Z. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.10.006 · Cited by 30 · see citing works
Luedders, B. A., Wheeler, A. M., Ascherman, D. P., Baker, J. F., Duryee, M. J., Yang, Y., Roul, P., Wysham, K. D., Monach, P. A., Reimold, A. M., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42812 · Cited by 25 · see citing works
Kalafatis, D., Löfdahl, A., Näsman, P., Dellgren, G., Wheelock, Å. M., Elowsson, L., Sköld, M. C., & Westergren‐Thorsson, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413421 · Cited by 25 · see citing works
“MMP7, described as a potential diagnostic and prognostic biomarker of IPF [39,40] specifically cleaves DCN [41], a proteoglycan involved in the fibrillization of collagens and acts as an inhibitor of the powerful profibrotic agent transforming growth factor (TGF)-β that induces myofibroblast differentiation [42–44].”
BackgroundWalking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 22 · see citing works
Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers
Drakopanagiotakis, F., Markart, P., & Steiropoulos, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210196 · Cited by 21 · see citing works
D’Agnano, V., Mariniello, D. F., Ruotolo, M., Quarcio, G., Moriello, A., Conte, S., Sorrentino, A., Zamparelli, S. S., Bianco, A., & Perrotta, F. (2024) · Life · doi:10.3390/life14020229 · Cited by 20 · see citing works
“MMP7 is one of the most promising prognostic biomarkers of IPF; MMP7 has been associated with mortality, and baseline concentrations were negatively correlated with DLCO [68].”
BackgroundPulito‐Cueto, V., Atienza‐Mateo, B., Batista-Liz, J., Mora-Gil, M. S., Cuesta, V. M. M., Fernandez, D. I., Cuervo, S. I., Portilla, C. A., Blanco, R., & López‐Mejías, R. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01128-2 · Cited by 22 · see citing works
Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis
Wang, Q., Xie, Z., Wan, N., Yang, L., Jin, Z., Jin, F., Huang, Z., Chen, M., Wang, H., & Feng, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002171 · Cited by 19 · see citing works
“MMP7 levels were significantly higher in plasma or serum,([4,6,8,42,49,50]) BALF,([4,42,51]) and lung tissue([42]) of patients with IPF as compared to HCs; and a serum cutoff value of 6 ng/mL could distinguish between these two groups.”
BackgroundNareznoi, D., Konikov-Rozenman, J., Petukhov, D., Breuer, R., & Wallach‐Dayan, S. B. (2020) · Cells · doi:10.3390/cells9020411 · Cited by 19 · see citing works
“The assessment of MMP-7 activity is considered to be clinically important for patients with IPF, chronic obstructive pulmonary disease (COPD), small cell lung cancer, adenocarcinoma, and squamous cell carcinoma [25,27,29,30,58,59].”
BackgroundCésar, E. C., López, L. L., Lara, E., Juan, M. V. H.-S., Romero, C. P., Palencia, J. L. R. S., Martín‐Montañez, E., & Garcia‐Fernandez, M. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143167 · Cited by 19 · see citing works
“Until now, several studies have demonstrated that MMP7 is a valuable biomarker for IPF alone, or in combination with other candidate biomarkers, such as MMP1, MPP8, IGFBP1, TNF SP-A, SP-D or KL-6 [5,6,45,46], but not for CTD-ILD.”
BackgroundInfluentialRecent advances in the non-invasive assessment of fibrosis using biomarkers
Tatler, A. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.010 · Cited by 18 · see citing works
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17 · see citing works
Research Progress of Fibroblasts in Human Diseases
Li, X., Li, N., Wang, Y., Han, Q., & Sun, B. (2024) · Biomolecules · doi:10.3390/biom14111478 · Cited by 19 · see citing works
Diagnosis of Idiopathic Pulmonary Fibrosis “Pragmatic Challenges in Clinical Practice”
Tzilas, V., Τzouvelekis, Α., Chrysikos, S., Papiris, S. A., & Bouros, D. E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00151 · Cited by 17 · see citing works
“Further studies using highly standardized sample collection procedures and collection matrices are needed to produce reproducible and reliable diagnostic and prognostic cutoff thresholds (54).”
BackgroundEmerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17 · see citing works
“MMP7 is overexpressed by basaloid cells and has become a validated marker of disease severity and progression in IPF [100,101].”
Identification of a unique temporal signature in blood and BAL associated with IPF progression
Norman, K. C., O’Dwyer, D. N., Salisbury, M. L., DiLillo, K. M., Lama, V. N., Xia, M., Gurczynski, S. J., White, E. S., Flaherty, K. R., Martínez, F. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67956-w · Cited by 16 · see citing works
Matson, S. M., Lee, S., Peterson, R., Achtar‐Zadeh, N., Boin, F., Wolters, P. J., & Lee, J. S. (2021) · European Respiratory Journal · doi:10.1183/13993003.01560-2021 · Cited by 16 · see citing works
Pulmonary fibrosis, part II: state-of-the-art patient management
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312347 · Cited by 16 · see citing works
“A recent report suggests that high plasma levels for matrix metalloproteinase-7 (MMP-7) may be particularly useful as a predictor of disease progression and mortality risk in IPF [103].”
BackgroundStatins’ still controversial role in pulmonary fibrosis: What does the evidence show?
Andreikos, D., Karampitsakos, Τ., Tzouvelekis, A., & Stratakos, G. K. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102168 · Cited by 15 · see citing works
Self-citationLi, R. M., Tan, D. B. A., Tedja, C., Cooper, W. A., Jo, H. E., Grainge, C., Glaspole, I., Goh, N. S. L., Ellis, S. J., Hopkins, P. M.-A., et al. (2025) · Respirology · doi:10.1111/resp.14894 · Cited by 14 · see citing works
Määttä, M., Laurila, H. P., Holopainen, S., Aaltonen, K., Lilja-Maula, L. I. O., Viitanen, S. J., & Rajamäki, M. M. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15970 · Cited by 13 · see citing works
“pro-form and active form) concentrations in the blood of IPF patients when compared with healthy controls, patients with other interstitial lung diseases, or those with chronic obstructive pulmonary disease.(12,14,15,30) In humans, MMP-7 is considered a profibrotic mediator(3) and a potential blood prognostic and diag…”
BackgroundResultNakatsuka, Y., Handa, T., Nakashima, R., Tanizawa, K., Kubo, T., Murase, Y., Sokai, A., Ikezoe, K., Hosono, Y., Watanabe, K., et al. (2019) · Rheumatology · doi:10.1093/rheumatology/kez065 · Cited by 14 · see citing works
Perez-Favila, A., Veloz, I. G., Hernandez-Marquez, L. S., Gutierrez-Vela, E. F., Flores‐Morales, V., & Martínez‐Fierro, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031562 · Cited by 13 · see citing works
“One study reported that MMP-7 correlates with clinical and functional predictors of disease severity and mortality, so it can be used to distinguish IPF from other chronic diseases [126].”
BackgroundBrůžová, M., Pavlova, M., Matěj, R., Šterclová, M., & Vašáková, M. (2021) · Diagnostics · doi:10.3390/diagnostics11040693 · Cited by 12 · see citing works
Ali, M. F., Dasari, H., Keulen, V. P. V., Cornec, D., Vasmatzis, G., Peikert, T., & Carmona, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-04199-2 · Cited by 12 · see citing works
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10 · see citing works
“MMP-7 found it to predict disease progression and long-term survival [122].”
BackgroundSerum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis
Araújo, M., Beltrão, M., Sokhatska, O., Melo, N., Mota, P. C., Bastos, H. N., Alexandre, A. T., Coelho, D. B., Delgado, L., & Morais, A. (2024) · ERJ Open Research · doi:10.1183/23120541.00553-2024 · Cited by 10 · see citing works
“Subsequent studies have further validated its prognostic value as a predictor of disease progression [8, 9].”
Insights into interstitial lung disease pathogenesis
Vasarmidi, E., Worrell, J. C., Persson, I. M., Yaqub, N., Miądlikowska, E., Barnig, C., Boots, A. W., Reynaert, N. L., & Ocaña, S. C. (2025) · Breathe · doi:10.1183/20734735.0261-2024 · Cited by 11 · see citing works
“Incorporating MMP-7 into prognostic models alongside other biomarkers, such as KL-6 or clinical parameters may enhance predictive accuracy [74, 92, 94].”
Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis
Machahua, C., Vicens‐Zygmunt, V., Ríos-Martín, J., Llatjós, R., Campuzano, I. E., Molina‐Molina, M., & Montes‐Worboys, A. (2022) · Experimental Lung Research · doi:10.1080/01902148.2022.2067265 · Cited by 10 · see citing works
Smoking and Idiopathic Pulmonary Fibrosis: A Meta-analysis
Fang, M., He, B., & Xiao, J. Y. (2024) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntae100 · Cited by 9 · see citing works
Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosis
Oldham, J. M., Johnson, K. W., Albers, G. J., Calamita, E., Mah, J., Ghai, P., Hewitt, R. J., Maher, T. M., Molyneaux, P. L., Huang, M., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00690-2022 · Cited by 9 · see citing works
Monteleone, G., Passantino, L., Simonetti, J., Iovene, B., Varone, F., Cameli, P., Sgalla, G., & Richeldi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145100 · Cited by 9 · see citing works
“Amid these promising candidates, the quantity of matrix metalloproteinases-7 (MMP-7) was significantly higher in the plasma samples of IPF patients compared to controls, suggesting its potential prognostic role, particularly in combination with other markers [31].”
Liu, M., Xue, M., Zhang, T., Lin, R., Guo, B., Chen, Y., Cheng, Z. J., & Sun, B. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24734 · Cited by 7 · see citing works
Zhao, A., Unterman, A., Hussein, N. S. A., Sharma, P., Flint, J., Yan, X., Adams, T. S., Justet, A., Sumida, T. S., Zhao, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558301 · Cited by 9 · see citing works
Self-citationNHLRC2 expression is increased in idiopathic pulmonary fibrosis
Kreus, M., Lehtonen, S. T., Hinttala, R., Salonen, J., Porvari, K., & Kaarteenaho, R. L. (2022) · Respiratory Research · doi:10.1186/s12931-022-02129-z · Cited by 7 · see citing works
The Role of Serum 1,25-Dihydroxy Vitamin D3 and PCT in Idiopathic Pulmonary Fibrosis
Li, Y., Zhai, Z., & Zhang, J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s386984 · Cited by 8 · see citing works
Genomic Fingerprint Associated with Familial Idiopathic Pulmonary Fibrosis: A Review
Ding, D., Gao, R., Xue, Q., Luan, R., & Yang, J. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.80358 · Cited by 7 · see citing works
“Plasma MMP7 has been proposed as a univariate predictor of early interstitial lung disease in firstdegree relatives of patients with familial interstitial pneumonia (158).”
BackgroundCan monocytes predict prognosis of idiopathic pulmonary fibrosis?
Kreuter, M., & Maher, T. M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30050-5 · Cited by 7 · see citing works
Chen, H., Tang, J., Liang, J., Huang, D., Pan, C., Liu, S., Du, X., & Tao, L. (2023) · Archives of Rheumatology · doi:10.46497/archrheumatol.2023.9547 · Cited by 5 · see citing works
“8,9 Both MMP-2 and -9 have a close association with the inflammatory procession of the body and are involved in the development of airway inflammation and pulmonary fibrosis, which are also able to be deemed as biomarkers for scaling alveolar injury degree.”
BackgroundGazing into the crystal ball: can treatment response be predicted in IPF?
Kreuter, M., & Maher, T. M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30234-0 · Cited by 5 · see citing works
Westermann-Clark, E., Soundararajan, R., Fukumoto, J., Patil, S. S., Stearns, T. M., Saji, S., Czachor, A., Hernández‐Cuervo, H., Breitzig, M., Krishnamurthy, S., et al. (2022) · Biomolecules · doi:10.3390/biom12020283 · Cited by 5 · see citing works
Enfermedad pulmonar intersticial difusa
Iribarnegaray, J. M., Arróspide, M. C., López, C. M., & Rojo, R. P. (2023) · Open Respiratory Archives · doi:10.1016/j.opresp.2023.100248 · Cited by 7 · see citing works
Kumar, S., Swaroop, S., Sahu, A., Kant, S., & Banerjee, M. (2023) · DNA and Cell Biology · doi:10.1089/dna.2023.0150 · Cited by 5 · see citing works
Amubieya, O., Todd, J. L., Neely, M. L., Kaner, R. J., Lasky, J. A., Namen, A. M., Heßlinger, C., Palmer, S. M., WEIGT, S. S., & Belperio, J. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312044 · Cited by 5 · see citing works
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 5 · see citing works
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials
Randall, M. J., Andersen, C. A. F., Brown, K. M., de Bernard, S., Ford, P., Kaminski, N., Kreuter, M., Lim, S., Maher, T. M., Prasad, N., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00893-2025 · Cited by 4 · see citing works
“Fibrosis markers periostin and matrix metalloproteinase MMP-7 associated with fibroblasts and aberrant basaloid cells [2, 9] respectively, are linked to progression and poor survival outcomes [6, 9, 11, 12].”
Self-citationBiomarkers of Progressive Fibrosing Interstitial Lung Diseases
Валентиновна, Б. Е., & Yurkova, Y. G. (2023) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2023-8-4-126-133 · Cited by 4 · see citing works
Serum biomarkers in idiopathic pulmonary fibrosis
Patrucco, F., Bellan, M., & Solidoro, P. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04049-5 · Cited by 3 · see citing works
Stewart, I., Jacob, J., Porter, J. C., Liu, B., Tatler, A. L., Gomez, N., Pugh, M., John, A. E., Allen, R. J., Blaikley, J., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106134 · Cited by 2 · see citing works
“With the exception of MMP-7, biomarker concentrations in the PHOSP-COVID cohort were largely comparable to healthy controls reported in previous studies, 10,15,40 highlighting that the extent of epithelial injury is not consistent with clinical presentations of ILD.”
InfluentialAge-related neutrophil activation in Hermansky-Pudlak Syndrome Type-1
Caro-Rivera, L. M., Malavez-Cajigas, S. J., Lacourt-Ventura, M., Rivera-Torres, A. P., Marcano-Jiménez, D. E., López-Colon, P., Muñiz‐Hernández, J., Rivera-Jiménez, E., Egozcue-Dionisi, M., ROMAN-CARLO, R. I., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03758-5 · Cited by 2 · see citing works
“Elevated MMP-7 and MMP-8 levels in older patients suggest increased extracellular matrix remodeling and neutrophil-driven inflammation, consistent with previous findings in both HPS-PF and IPF, where MMPs have been implicated in disease progression [26, 27].”
Darawshy, F., Padawer, D., Qadan, A., Salaymeh, Y., & Berkman, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09245-y · Cited by 3 · see citing works
Biomarkers in Interstitial Lung Diseases
Fernandez, I. E., & Eickelberg, O. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_11 · Cited by 2 · see citing works
MMP28 in Idiopathic Pulmonary Fibrosis: Beyond the Extracellular Matrix
Atamas, S. P. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0038ed · Cited by 2 · see citing works
Валентиновна, Б. Е., Yurkova, Y. G., Гилевич, И. В., & Shulzhenko, L. V. (2025) · PULMONOLOGIYA · doi:10.18093/0869-0189-2025-35-5-686-693 · Cited by 1 · see citing works
Benattia, A., Porcher, R., Terry, S., Andrieu, M., Lorillon, G., & Tazi, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-40540-4 · Cited by 1 · see citing works
“Notably, blood levels of MMP-7 are increased in IPF patients, and the level of this MMP has been validated as a blood biomarker of disease progression 36,37 .”
Ruenwilai, P., Tajarernmuang, P., Chattipakorn, S. C., Chattipakorn, N., & Shinlapawittayatorn, K. (2026) · Lung · doi:10.1007/s00408-026-00887-x · Cited by 1 · see citing works
Biobanking for Pulmonary, Critical Care, and Sleep Medicine
Winkler, J., & Herzog, E. L. (2020) · Respiratory medicine · doi:10.1007/978-3-030-31507-8_9 · Cited by 1 · see citing works
Self-citationEvolving Genomics of Pulmonary Fibrosis
Ibarra, G. L., Herazo‐Maya, J. D., & Kaminski, N. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_9 · Cited by 1 · see citing works
Self-citationBaydar, O., Özyılmaz, E., Saygıdeğer, Y., & Güzel, E. (2022) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1137742 · Cited by 1 · see citing works
- Authors
- Tzouvelekis, A., Herazo‐Maya, J. D., Slade, M., Chu, J., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., Gulati, M., Antin‐Ozerkis, D., Herzog, E. L., & Kaminski, N.
- Affiliations
- Pulmonary, Critical Care, and Sleep Medicine Yale School of Medicine New Haven Connecticut USA
- Yale University (US)
- Corresponding author
- Kaminski, Naftali
- ORCID
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2016-10-19
- Volume
- 22
- Issue
- 3
- Pages
- 486-493
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- PMC
- PMC5352520
- OpenAlex
- W2533435663
- Cited by
- 130
- References
- 42
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 17 · 2023: 17 · 2022: 13 · 2021: 11 · 2020: 23 · 2019: 8 · 2018: 13 · 2017: 9
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Respirology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UO1 HL108642, R01 HL127349, R01 HL109033)
- Biogen
- Gilead Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, matrix metalloproteinase-7, MMP-7, prognostic factors, all-cause mortality, transplant-free survival, diffusing capacity for carbon monoxide, forced vital capacity, biomarker validation
- MeSH terms
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Pulmonary Diffusing Capacity, Reproducibility of Results, Cohort Studies, Biomarkers, Survival Rate, Proportional Hazards Models, Case-Control Studies, Lung Transplantation, Matrix Metalloproteinase 7, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
